Stocks that tracked hedge funds and asset managers added to or newly bought in their latest 13F filings, while retail attention is still low — with the fund-by-fund share changes, estimated entry prices and an AI read on why they may be buying.
Next scan: tomorrow by 9:00 AM ET. A new scan is posted every Saturday by 9:00 AM ET.
5stocks qualified
5funds adding
3new positions
$3.17Bheld by those funds
AIThis scan
This scan compared the two most recent 13F windows filed by the five funds on the watchlist — reportDates 2026-03-31 (latest, filed by mid-May) versus 2025-12-31 (prior). Roughly 895 US-listed CUSIPs cleared the raw acceleration filter (more funds adding than trimming; aggregate share count up ≥25% Q/Q or ≥2 new positions; single-fund block-dominance exempted only for Berkshire). Five names survived the quality rails, the retail-attention filter, and the seven-trading-day earnings blackout. The single most surprising finding of the run is one we explicitly excluded from the stock list: Berkshire's brand-new 39.8M-share ($2.65B) Delta Air Lines position — the first airline stake since Buffett publicly repudiated the industry in 2020. It cleared the acceleration test, but retail attention on DAL exploded after the May 15 filing (DAL now +34% YTD, wall-to-wall press coverage), so it fails the "retail hasn't caught on" gate. We reference it here for context and skip it in the picks. Also worth noting: Berkshire fully exited UnitedHealth, Amazon, Visa, Mastercard, Domino's, Pool, Charter, Heico, Lamar and Aon in the same quarter, and trimmed Constellation Brands by ~95% — Greg Abel's first quarter as CEO looks like a portfolio simplification.
How this scan was run
Acceleration was defined per CUSIP as: (a) net buying funds > net selling funds, (b) aggregate shares up ≥25% Q/Q OR ≥2 funds opening a new position, and (c) no single non-Berkshire fund providing >80% of the incremental shares (Berkshire block buys are the signal, so exempted). Put positions were excluded (hedges, not accumulation). Quant filers (Renaissance, Two Sigma, Citadel) were down-weighted in thesis writing — a name supported only by quants ranks below one with Berkshire or Bridgewater involvement. All five picks have ≥1 non-quant supporter (Berkshire for LEN; Bridgewater for CTAS, AZO, EHC, A). Retail-attention gate required ≥2 of: Google Trends ≤25, ≤15 mainstream articles in 30 days, not on r/wallstreetbets top-100 or StockTwits trending, options call/put OI ratio <2.0 — all five clear this comfortably as low-buzz names. Quality rails: mkt cap ≥$1B, ADV ≥$10M, no ETFs/SPACs/leveraged, no earnings within 7 trading days. Delta Air Lines and New York Times were dropped for attention (DAL) and earnings-window (NYT reports Aug 5, exactly on the 7-day boundary) respectively. All five funds returned holdings via fetch_13f_holdings; none failed. CUSIPs 526057104 (LEN Class A), 172908105, 053332102, 00846U101, 29261A100 resolved unambiguously to single tickers. Average-entry-price figures below are Q1-end mark-to-market (value ÷ shares) — an estimate, not true cost basis, which 13F does not report.
#1
LEN
Lennar Corporation
Consumer DiscretionaryMkt cap $22.0BNext earnings Sep 17, 2026
Price
$84.64
Est. fund entry
$86.84-2.5%
Shares held
14.3M
Position value
$1.24B
Funds that added
Fund
Prior shares
Shares now
Change
Berkshire Hathaway
7.05M
10.1M
+43.2%
Two Sigma Investments
1.54M
2.60M
+69.5%
Citadel Advisors
1.23M
1.25M
+1.9%
Retail attention 3 of 4 signals quiet
Google Trends18/100quiet
News, 30 days22 articlesbusy
Call/put OI1.30quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Berkshire added 3M shares (+43%) to a Lennar position it first opened in Q4 2024, taking the stake past $875M — the largest single-quarter addition to LEN in Berkshire's history. Two Sigma nearly doubled alongside. The setup is a rate-cut cycle trade: Lennar trades near book value, sits on record cash post-Millrose spin, and is the lowest-cost land-light builder in a market where existing-home supply is still tight. Buffett/Abel rarely chase homebuilders — the 43% top-up implies they see the current 8x forward P/E as protection against the cycle risk. Catalyst retail hasn't priced: land-light model means margin resilience if rates fall AND if rates stay high — an asymmetric setup the sell side still models as pure cyclical.
What would prove it wrong
Homebuilder margins are compressing on incentive spend. A hotter-than-expected Q3 CPI print pushes rate-cut expectations out again and the trade unwinds. LEN is also the most-shorted name in the group, so a squeeze cuts both ways.
#2
EHC
Encompass Health Corporation
Health CareMkt cap $11.0BNext earnings Oct 28, 2026
Price
$112.89
Est. fund entry
$96.73+16.7%
Shares held
3.05M
Position value
$294.9M
Funds that added
Fund
Prior shares
Shares now
Change
Two Sigma Investments
804.9K
2.22M
+176.1%
Citadel Advisors
125.1K
515.1K
+311.8%
Renaissance Technologies
68.2K
265.0K
+288.6%
Bridgewater Associates
35.4K
46.4K
+31.1%
Retail attention 4 of 4 signals quiet
Google Trends6/100quiet
News, 30 days8 articlesquiet
Call/put OI1.00quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
All four active managers added — an unusual four-of-four consensus for a $11B mid-cap. Aggregate share count nearly tripled Q/Q. Bridgewater's presence is the tell: the macro shop rarely bothers with sub-$15B healthcare, but rehab hospitals are a demographic pure-play (Medicare-age population inflecting hard through 2030) with 176-hospital scale that new entrants cannot replicate. Encompass just raised its dividend 11% and guided to $6.4B revenue at the high end. Catalyst: capacity expansion via the 2027 hospital pipeline is being modeled by the sell side at 4-5% revenue CAGR, but bed-day demand is running hot enough that 8-9% is plausible.
What would prove it wrong
CMS reimbursement rules for inpatient rehab (IRF-PPS) get revisited every rulemaking cycle. Any margin compression from a rate cut on the high-severity case-mix index would hit hard. Stock is up 20% since Q1 quarter-end so the smart-money entry is already stale on price.
#3
CTAS
Cintas Corporation
IndustrialsMkt cap $82.0BNext earnings Sep 17, 2026
Price
$205.91
Est. fund entry
$169.14+21.7%
Shares held
3.99M
Position value
$674.4M
Funds that added
Fund
Prior shares
Shares now
Change
Two Sigma Investments
1.22M
2.36M
+93.8%
Citadel Advisors
845.1K
1.62M
+91.2%
Bridgewater Associates
—
11.5K
New position
Retail attention 4 of 4 signals quiet
Google Trends11/100quiet
News, 30 days12 articlesquiet
Call/put OI1.00quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Two Sigma and Citadel both roughly doubled their positions in the same quarter — statistically unusual because these two shops usually take opposite sides of the same trade. Bridgewater initiated a starter position, which for a macro shop signals a services-inflation thesis, not a stock-specific call. Cintas is the largest US uniform-rental operator with 8%+ organic revenue growth for 12 consecutive quarters, and its route-density moat compounds as fuel and labor prices climb. Q4 results (July 15) beat and guidance held. Catalyst: the sell-side still models 6-7% top-line growth for FY27, but Cintas' pricing pass-through on its 1M+ customer base has been running above CPI — a mid-single-digit rerate feels underpriced.
What would prove it wrong
Trades at ~48x forward earnings — any hint of organic-growth deceleration hits the multiple. A US small-business hiring downturn is the direct read-through to route volumes. Post-earnings pop already captured some of the near-term upside.
#4
AZO
AutoZone, Inc.
Consumer DiscretionaryMkt cap $50.0BNext earnings Sep 22, 2026
Price
$2,957.41
Est. fund entry
$3,377.78-12.4%
Shares held
180.6K
Position value
$610.0M
Funds that added
Fund
Prior shares
Shares now
Change
Citadel Advisors
73.9K
89.0K
+20.4%
Two Sigma Investments
33.1K
56.9K
+72.0%
Renaissance Technologies
27.4K
34.2K
+24.6%
Bridgewater Associates
—
499
New position
Retail attention 4 of 4 signals quiet
Google Trends14/100quiet
News, 30 days11 articlesquiet
Call/put OI1.20quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Four-of-four managers accumulating, including a Bridgewater initiation — for a $50B name, that reads as a defensive-consumer tilt call. The Q1-end mark ($3,378) is 14% above spot ($2,957), meaning smart money got in higher than today's price — the entry is currently underwater and yet nobody trimmed. That's a rare tell. AutoZone's commercial DIFM business has grown 15%+ for six straight quarters and is now ~30% of sales; average vehicle age at 12.8 years is a structural tailwind. Catalyst: an economic slowdown that keeps consumers repairing rather than replacing vehicles — historically AZO's best environment — is exactly what Bridgewater's 2026 macro book flags.
What would prove it wrong
Q3 (May) earnings missed and the stock dropped 9% on the print — the setup for the September Q4 print matters. Extended-loan share on new-car sales has been climbing, which normalizes fleet turnover and cuts the tailwind. Buyback pace has slowed vs. peak years.
#5
A
Agilent Technologies, Inc.
Health CareMkt cap $39.0BNext earnings Aug 26, 2026
Price
$138.57
Est. fund entry
$113.98+21.6%
Shares held
3.05M
Position value
$347.4M
Funds that added
Fund
Prior shares
Shares now
Change
Citadel Advisors
646.2K
2.00M
+209.0%
Two Sigma Investments
265.4K
677.3K
+155.2%
Renaissance Technologies
—
300.3K
New position
Bridgewater Associates
13.1K
73.7K
+462.8%
Retail attention 4 of 4 signals quiet
Google Trends5/100quiet
News, 30 days7 articlesquiet
Call/put OI0.90quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Aggregate share count more than tripled Q/Q — the largest acceleration in the shortlist by percentage. Bridgewater's Agilent position grew 5.6x, a size unusual for a slower-moving book. Life-sciences instruments were the worst-hit sector coming out of the 2022-2024 China destocking, and Agilent — the leader in liquid chromatography and mass spec — was the deepest drawdown name. The pattern of ALL four funds increasing suggests they see the end of the China pharma-CapEx pause. Catalyst: mgmt guided flat-to-up organic growth for the back half; Q3 (Aug 26) is the reveal. A single positive datapoint from Wuxi/Beijing academic labs re-accelerating gets Agilent to a fresh cycle high.
What would prove it wrong
Stock has already run 22% since the Q1 quarter-end that filings capture, so the smart-money entry is stale. If Aug 26 print misses on China, the whole life-sciences complex re-rates down together. Bio-Rad, Waters, and Danaher all report same window — cross-read risk.
Based on public SEC 13F filings. Funds file them up to 45 days after each quarter ends, so they show positions at quarter-end, not today. Average entry prices are estimates (filing value ÷ shares) — 13F filings don't report cost basis. The summaries, theses and risks are written by AI as a research aid — they are not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Institutional Flow tracks the quarterly 13F filings of a watchlist of hedge funds
and asset managers and flags the stocks several of them are accelerating into — new positions or sharply larger ones —
while search interest, news coverage and options positioning say the retail crowd hasn't noticed yet. It is free, and a
new scan is posted every Saturday by 9:00 AM ET. How to read Institutional Flow →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.